PENTASA References

  1. Sinha A, Ball DJ, Connor AL, Nightingale J, Wilding IR. Intestinal performance of two mesalamine formulations in patients with active ulcerative colitis as assessed by gamma scintigraphy. Pract Gastroenterol. 2003;27:56-69.
  2. Wilding IR. A scintigraphic study to evaluate what happens to Pentasa® and Asacol® in the human gut. Pract Gastroenterol. November 1999;(suppl):1-8.
  3. Rijk MCM, Van Schaik A, Van Tongeren JHM. Disposition of mesalazine from mesalazine-delivering drugs in patients with inflammatory bowel disease, with and without diarrhoea. Scand J Gastroenterol. 1992;27:863-868.
  4. Nugent SG, Kumar D, Rampton DS, Evans DF. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut. 2001;48:571-577.
  5. Hardy JG, Harvey WJ, Sparrow RA, et al. Localization of drug release sites from an oral sustained-release formulation of 5-ASA (PENTASA®) in the gastrointestinal tract using gamma scintigraphy. J Clin Pharmacol. 1993;33:712-718.
  6. Cuffari C, Present DH, Bayless TM, Lichtenstein GR. Optimizing therapy in patients with pancolitis. Inflamm Bowel Dis. 2005;11:937-946.
  7. DiPiro JT, Schade RR. Inflammatory bowel disease. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach. 4th ed. Stamford, Conn: Appleton & Lange; 1999:571-585.
  8. Hanauer S, Schwartz J, Robinson M, et al, and the Pentasa® Study Group. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Am J Gastroenterol. 1993;88:1188-1197.
  9. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006;23:577-585.
  10. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherance and the outcomes of patients with quiescent ulcerative colits. Am J Med. 2003;114:39-43.
  11. Robinson M, Hanauer S, Hoop R, Zbrozek A, Wilkinson C. Mesalamine capsules enhance the quality of life for patients with ulcerative colitis. Aliment Pharmacol Ther. 1994;8:27-34.
  12. Colazal® (balsalazide disodium) full prescribing information, Salix Pharmaceuticals, 2005.
  13. Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2007;5:95-102.

Important Safety Information

  • PENTASA is indicated for the induction of remission and for the treatment of patients with mildly to moderately active ulcerative colitis.
  • PENTASA is generally well tolerated. In worldwide clinical trials (N>2100), the most common adverse events were diarrhea (3.4%), headache (2.0%), nausea (1.8%), abdominal pain (1.7%), dyspepsia (1.6%), vomiting (1.5%), and rash (1.0%). As with other mesalamine products, serious adverse events may occur. PENTASA is contraindicated in patients with a hypersensitivity to salicylates. Caution should be used in patients with impaired hepatic or renal function. Patients with pre-existing renal disease, increased BUN or serum creatinine, or proteinuria should be monitored during PENTASA therapy.